Ocular Safety and Visual Acuity Stability in Pediatric Patients With Optic Pathway Gliomas and Orbital Plexiform Neurofibromas Treated With BRAF and MEK Inhibitors

Documenti analoghi

• Incidence of Bevacizumab‐Associated Toxicity in Children With Low‐Grade Glioma With and Without Neurofibromatosis Type 1
  di: Alexander Yelak, et al.
  Pubblicazione: (2025)
• BRAF/MEK inhibitors use to treat ventriculoperitoneal shunt‐associated ascites in pediatric low‐grade gliomas
  di: Nisreen Amayiri, et al.
  Pubblicazione: (2024)
• Comment on: “Challenging the Odds: Long‐Term Survival in Pediatric Diffuse Midline Glioma With H3 K27M and BRAF V600 Co‐Mutations Treated With Upfront Radiotherapy and Targeted Therapy”
  di: Natália Dassi, et al.
  Pubblicazione: (2026)
• Cerebrospinal Fluid Liquid Biopsy Enables Targeted Therapy Without Tissue Diagnosis in Pediatric Low‐Grade Gliomas With BRAF V600E Mutation
  di: Hannah Sultan, et al.
  Pubblicazione: (2026)
• Granulocyte Transfusions in Pediatric Hemato‐Oncology: Neutrophil Response and CRP Kinetics
  di: Aviv Sever, et al.
  Pubblicazione: (2025)